Equities

CANbridge Pharmaceuticals Inc

CANbridge Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)0.345
  • Today's Change0.01 / 2.99%
  • Shares traded15.00k
  • 1 Year change-76.85%
  • Beta--
Data delayed at least 15 minutes, as of May 21 2024 07:25 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

CANbridge Pharmaceuticals Inc is a China-based company mainly engaged in the research, development and commercialization of rare disease treatments. The Company's main businesses are the development, production, promotion and sales of medical products. The Company's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The Company's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The Company is also engaged in the development of gene therapy.

  • Revenue in HKD (TTM)111.11m
  • Net income in HKD-409.19m
  • Incorporated2017
  • Employees100.00
  • Location
    CANbridge Pharmaceuticals IncRongchuang Roadchaoyang DistrictSuite 301, 3f, Timeloit No.17SUZHOU 02142-1530ChinaCHN
  • Phone+86 1 084148018
  • Fax+86 1 084148017
  • Websitehttps://www.canbridgepharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Huakang Biomedical Holdings Co Ltd26.60m-6.25m51.55m96.00--0.7822--1.94-0.015-0.0150.0640.13170.3742.692.57277,105.70-8.78-6.96-10.62-8.0164.4966.27-23.48-20.233.82--0.0429---2.77-3.00-88.03---12.03--
Extrawell Pharmaceutical Holdings Ltd68.62m-154.28m90.82m169.00--0.0873--1.32-0.0776-0.07760.02090.43540.05387.479.89379,132.60-12.004.62-12.504.8847.3651.97-223.0773.993.38-0.05140.09680.00-1.82-3.28-1.0133.99121.54--
Regent Pacific Group Ltd2.47m-195.43m94.78m17.00------38.32-0.8681-0.86810.011-0.0530.0218--12.19145,486.20-172.08-50.00-694.26-59.04-----7,901.89-2,685.21--------574.47-44.7231.24---50.60--
Sanai Health Industry Group Co Ltd131.88m20.13m107.03m68.005.060.31476.000.81160.00550.00550.03480.0890.3179188.038.441,939,409.003.482.314.723.6528.7734.8710.956.566.22--0.18810.00-30.6016.04-36.23---75.21--
China Health Group Inc23.14m-62.87m111.48m42.00--1.22--4.82-0.0632-0.06320.02330.0920.1438--0.246550,987.10-39.076.84-51.269.5238.3374.98-271.7019.19----0.000.0063.67-18.51-267.82--30.37--
BioSino Bio-technology and Science Inc312.23m-12.58m123.00m537.00--0.5413--0.3939-0.0869-0.08692.161.570.49562.791.46581,437.60-3.30-3.84-8.55-10.1744.0640.17-6.66-6.980.9033--0.3956---22.52-0.9513-243.70---16.58--
Canbridge Pharmaceuticals Inc111.11m-409.19m142.32m100.00------1.28-0.9642-0.96420.2618-0.10120.18754.164.091,111,125.00-69.04---154.20--62.37---368.26--0.6132-41.341.39--30.26--21.64------
Kontafarma China Holdings Ltd809.11m-28.84m184.42m720.00--0.17444.170.2279-0.0052-0.00520.1450.18920.42063.227.031,123,760.00-3.18-1.33-4.22-2.1858.2554.70-7.55-4.121.28-6.190.2392---9.50-17.3266.02------
Modern Chinese Medicine Group Co Ltd371.64m52.70m243.00m191.004.610.47584.100.65390.08790.08790.61940.85130.66815.453.801,945,762.009.4720.7610.7525.8230.2841.0214.1820.117.98206.120.00022.54-13.9114.67-44.440.230396.96--
Shenzhen Neptunus Intrlng Bi tchnq CoLtd1.15bn26.06m253.38m1.44k9.720.25834.870.22030.01550.01550.68540.58460.74373.036.51796,517.901.013.461.575.1341.8149.141.364.291.95--0.08110.007.924.19-55.60-12.89-11.10--
Wai Yuen Tong Medicine Holdings Limited1.36bn36.42m255.40m1.96k7.500.11941.490.18790.03030.03031.131.900.20140.42422.81700,208.600.8907-0.07331.54-0.119649.0842.524.42-0.4560.56631.490.31960.00-7.558.7581.16---12.06--
PuraPharm Corp Ltd406.86m-106.08m308.80m662.00--2.02--0.759-0.2685-0.26851.030.38710.43741.044.19614,590.60-11.40-9.20-34.00-19.7053.2459.44-26.07-19.330.3046-2.280.7349---9.20-11.4111.76---13.68--
Hin Sang Group (Interntnl) Hldng Co Ltd92.79m-35.72m316.62m265.00--1.44--3.41-0.0327-0.03270.0850.2020.15242.299.49366,766.80-5.81-4.06-8.74-5.2655.9561.98-38.14-20.980.1129-1.150.5766---32.42-15.45-315.54---36.30--
Data as of May 21 2024. Currency figures normalised to CANbridge Pharmaceuticals Inc's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

12.88%Per cent of shares held by top holders
HolderShares% Held
Athos Capital Ltd.as of 15 Dec 202352.67m12.40%
Janus Henderson Investors UK Ltd.as of 31 Mar 20241.06m0.25%
Janus Henderson Investors US LLCas of 31 Mar 2024964.96k0.23%
RA Capital Management LPas of 19 Dec 20230.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.